Hertha sells VNDA 11.88: Gulino served as a senior commercial attorney at Zeneca, Inc. Mr.

Gulino served as Vice President and General Counsel of Ameritox, Ltd., a clinical drug testing laboratory. Prior to this position, Mr. Gulino has over 20 years of strategic and legal experience representing life sciences and healthcare companies. A new report commissioned by the U.S. government contends that most Americans will encounter at least one diagnostic error in their lifetime, sometimes with severe consequences for their physical and mental health. In the past 52 weeks, Vanda Pharmaceuticals share prices have been bracketed by a low of $8.34 and a high of $15.51 and are now at $13.22, 59% above that low price. Patent number 8,586,610 ('610), rejected Roxane's proposed construction of all the disputed claim terms.


Trisha:
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of novel therapies addressing high unmet medical needs.

Leeanne:
Reverberi acted as a corporate advisor supporting several companies in the development of their commercial and geographical expansion strategies. Mr.

Georgiana:
Reverberi has more than 20 years of experience in the pharmaceutical industry, holding senior management and regional leadership positions over the last 10 years.

Jestine:
Equities analysts predict that Vanda Pharmaceuticals will post ($0.72) earnings per share for the current fiscal year.

Sibyl:
Piper Jaffray reaffirmed an overweight rating and issued a $16.00 price objective on shares of Vanda Pharmaceuticals in a report on Thursday, July 30th.

Adriana:
Canaccord Genuity restated a buy rating and set a $18.00 price target on shares of Vanda Pharmaceuticals in a research report on Thursday, July 30th.

Danae:
Canaccord Genuity reissued a buy rating and set a $18.00 price objective on shares of Vanda Pharmaceuticals in a report on Thursday.

Sheron:
In other news, CEO Mihael Hristos Polymeropoulos sold 186,395 shares of the stock in a transaction that occurred on Friday, May 22nd.

Brenda:
Equities research analysts forecast that Vanda Pharmaceuticals will post ($0.91) EPS for the current fiscal year.

Bryanna:
The business earned $27.60 million during the quarter, compared to the consensus estimate of $24.55 million.

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)
//stockhand.net/us/?q=nasdaq%3Avnda&id=443860